Astellas Provides Update on Fezolinetant New Drug Application in U.S.

TOKYO, Feb. 19, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced the U.S. Food and Drug Administration (FDA) notified the company that it is extending the original priority...

https://www.drugs.com/nda/fezolinetant_230220.html

Source: Drugs.com - New Drug Applications - February 20, 2023 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications | Pharmaceuticals